{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:03:48Z","timestamp":1781021028516,"version":"3.54.1"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["P01AI162242"],"award-info":[{"award-number":["P01AI162242"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI183970"],"award-info":[{"award-number":["R01AI183970"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U24AI126683"],"award-info":[{"award-number":["U24AI126683"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI186995"],"award-info":[{"award-number":["R01AI186995"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibodies are central players in adaptive immunity, providing protection against a wide array of pathogens through mechanisms such as neutralization, opsonization, recruitment of effector immune cells, complement activation, and engagement. However, in other contexts, these same effector functions can contribute to immunopathology, particularly when antibodies are developed against self-antigens, resulting in autoimmunity. Understanding the role antibodies play in preventing or causing disease is often supported by studies in model systems wherein manipulation of immunoglobulin G (IgG) levels can be used as an experimental tool. Here, we report in simian immunodeficiency virus (SIV) infected pigtail macaques (Macaca nemestrina) the capacity of two orthogonal strategies to systemically deplete IgG: treatment with a primatized neonatal Fc receptor blocking antibody (anti-FcRn) modelled on rozanolixizumab that restricts IgG rescue and recycling, and administration of the IgG protease IdeS that cleaves the Fc domain. Under the conditions evaluated, we observed more rapid and effective, although not necessarily more durable, IgG depletion mediated by IdeS, reducing levels by 74.1\u201395.1%, compared with a lesser reduction of 31.3\u201366.9% with anti-FcRn treatment. We observed a similar degree of depletion, comparable kinetics of rebound among SIV antigen-specific fractions as total IgG, but differential balance among IgG subclasses following treatment in some cases. In sum, this study in a non-human primate model describes the efficacy and downstream impacts of new tools to modify humoral immune states, providing insight into the balance between protective and pathological effects of IgG antibodies.<\/jats:p>","DOI":"10.1093\/cei\/uxag029","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:27:59Z","timestamp":1778675279000},"source":"Crossref","is-referenced-by-count":0,"title":["Depletion and recovery of IgG following treatment with an anti-FcRn antibody and IdeS in pigtail macaques"],"prefix":"10.1093","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-7517","authenticated-orcid":false,"given":"Kara M","family":"Rzasa","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College , Hanover, NH ,","place":["USA"]},{"name":"Thayer School of Engineering, Dartmouth College , Hanover, NH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Zikos","sequence":"additional","affiliation":[{"name":"Department of Medicine, UMass Chan Medical School , Worcester, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Penney","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Tulane School of Medicine , Covington, LA ,","place":["USA"]},{"name":"Tulane National Biomedical Research Center, Tulane University , New Orleans, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith R","family":"Schiro","sequence":"additional","affiliation":[{"name":"Tulane National Biomedical Research Center, Tulane University , New Orleans, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara A","family":"Doyle-Meyers","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Tulane School of Medicine , Covington, LA ,","place":["USA"]},{"name":"Tulane National Biomedical Research Center, Tulane University , New Orleans, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyone P","family":"Aye","sequence":"additional","affiliation":[{"name":"Tulane National Biomedical Research Center, Tulane University , New Orleans, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S","family":"Veazey","sequence":"additional","affiliation":[{"name":"Tulane National Biomedical Research Center, Tulane University , New Orleans, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Hoxie","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Maness","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Tulane School of Medicine , Covington, LA ,","place":["USA"]},{"name":"Tulane National Biomedical Research Center, Tulane University , New Orleans, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo M","family":"Magnani","sequence":"additional","affiliation":[{"name":"Department of Medicine, UMass Chan Medical School , Worcester, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":false,"given":"Margaret E","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College , Hanover, NH ,","place":["USA"]},{"name":"Thayer School of Engineering, Dartmouth College , Hanover, NH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026060911360989400_uxag029-B1","doi-asserted-by":"crossref","first-page":"1304365","DOI":"10.3389\/fimmu.2023.1304365","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2023","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B2","volume-title":"Antibody Fc","author":"Ackerman","year":"2014"},{"key":"2026060911360989400_uxag029-B3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"Igg subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B4","doi-asserted-by":"crossref","first-page":"e2406192121","DOI":"10.1073\/pnas.2406192121","article-title":"Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding","volume":"121","author":"Frischauf","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026060911360989400_uxag029-B5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fimmu.2020.00740","article-title":"Fc\u03b3r binding and ADCC activity of human IgG allotypes","volume":"11","author":"De Taeye","year":"2020","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/ITT.S274746","article-title":"Immunoglobulin G2 antibody as a potential target for COVID-19 vaccine","volume":"9","author":"Andualem","year":"2020","journal-title":"Immunotargets Ther"},{"key":"2026060911360989400_uxag029-B7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1535-7163.MCT-18-0341","article-title":"Immune effector functions of human IgG2 antibodies against EGFR","volume":"18","author":"R\u00f6sner","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026060911360989400_uxag029-B8","doi-asserted-by":"crossref","first-page":"780922","DOI":"10.3389\/fimmu.2022.780922","article-title":"The role of innate immunity in natural elite controllers of HIV-1 infection","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B9","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/gutjnl-2025-335375","article-title":"The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications","volume":"74","author":"Piseddu","year":"2025","journal-title":"Gut"},{"key":"2026060911360989400_uxag029-B10","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.4049\/jimmunol.1200090","article-title":"Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment","volume":"188","author":"Warncke","year":"2012","journal-title":"J Ommunol"},{"key":"2026060911360989400_uxag029-B11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fimmu.2019.00697","article-title":"Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function","volume":"10","author":"Crowley","year":"2019","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B12","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.4049\/jimmunol.2000501","article-title":"Functional interactions of common allotypes of rhesus macaque Fc\u03b3R2A and Fc\u03b3R3A with human and macaque IgG subclasses","volume":"205","author":"Grunst","year":"2020","journal-title":"J Immunol"},{"key":"2026060911360989400_uxag029-B13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s42003-022-04216-9","article-title":"Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells","volume":"5","author":"Staupe","year":"2022","journal-title":"Commun Biol"},{"key":"2026060911360989400_uxag029-B14","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J Clin Invest"},{"key":"2026060911360989400_uxag029-B15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","article-title":"Complement therapeutics in autoimmune disease","volume":"10","author":"Thurman","year":"2019","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026060911360989400_uxag029-B17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026060911360989400_uxag029-B18","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"2026060911360989400_uxag029-B19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2026060911360989400_uxag029-B20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","article-title":"Targeting the neonatal fc receptor in autoimmune diseases: pipeline and progress","volume":"39","author":"Gj\u00f8lberg","year":"2025","journal-title":"BioDrugs"},{"key":"2026060911360989400_uxag029-B21","doi-asserted-by":"crossref","first-page":"e12833","DOI":"10.1111\/xen.12833","article-title":"The impact of IdeS (imlifidase) on allo-specific, xeno-reactive, and protective antibodies in a sensitized rhesus macaque model","volume":"31","author":"DeLaura","year":"2024","journal-title":"Xenotransplantation"},{"key":"2026060911360989400_uxag029-B22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"Ides, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G","volume":"21","author":"Von Pawel-Rammingen","year":"2002","journal-title":"EMBO J"},{"key":"2026060911360989400_uxag029-B23","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1136\/bmjno-2023-000536","article-title":"Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial","volume":"6","author":"Benatar","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"2026060911360989400_uxag029-B24","doi-asserted-by":"crossref","first-page":"611661","DOI":"10.3389\/fimmu.2020.611661","article-title":"The influence of B cell depletion therapy on naturally acquired immunity to Streptococcus pneumoniae","volume":"11","author":"Ercoli","year":"2020","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1172\/JCI42695","article-title":"Pathogen-specific antibodies: codependent no longer","volume":"120","author":"Janoff","year":"2010","journal-title":"J Clin Invest"},{"key":"2026060911360989400_uxag029-B26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncomms1100","article-title":"B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection","volume":"1","author":"Huang","year":"2010","journal-title":"Nat Commun"},{"key":"2026060911360989400_uxag029-B27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijid.2021.04.068","article-title":"Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach","volume":"107","author":"D\u2019Abramo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026060911360989400_uxag029-B28","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1535-7163.MCT-17-0108","article-title":"Enzymatic inactivation of endogenous IgG by IdeS enhances therapeutic antibody efficacy","volume":"16","author":"J\u00e4rnum","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026060911360989400_uxag029-B29","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"mAbs"},{"key":"2026060911360989400_uxag029-B30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026060911360989400_uxag029-B31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026060911360989400_uxag029-B32","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026060911360989400_uxag029-B33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/psp4.12739","article-title":"Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: translation from preclinical stages to the clinic","volume":"11","author":"Lledo-Garcia","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026060911360989400_uxag029-B34","doi-asserted-by":"crossref","first-page":"2300155","DOI":"10.1080\/19420862.2023.2300155","article-title":"Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fc\u03b3 receptors and functional impact on immune cells in vitro","volume":"16","author":"Qureshi","year":"2024","journal-title":"mAbs"},{"key":"2026060911360989400_uxag029-B35","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for Myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B36","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"2026060911360989400_uxag029-B37","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized Myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"2026060911360989400_uxag029-B38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in Myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol Ther"},{"key":"2026060911360989400_uxag029-B39","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s12325-026-03543-1","article-title":"Indirect comparison of nipocalimab versus efgartigimod and rozanolixizumab in the treatment of generalized Myasthenia gravis","volume":"43","author":"Jacob","year":"2026","journal-title":"Adv Ther"},{"key":"2026060911360989400_uxag029-B40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.37349\/ei.2024.00145","article-title":"Safety and tolerability of anti-FcRn monoclonal antibody in thyroid autoimmunity","volume":"4","author":"Wolf","year":"2024","journal-title":"Explor Immunol"},{"key":"2026060911360989400_uxag029-B41","author":"Union Chimique Belge"},{"key":"2026060911360989400_uxag029-B42","author":"DelveInsight"},{"key":"2026060911360989400_uxag029-B43","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1128\/IAI.70.12.6646-6651.2002","article-title":"Endos and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis","volume":"70","author":"Collin","year":"2002","journal-title":"Infect Immun"},{"key":"2026060911360989400_uxag029-B44","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/19420862.2017.1364325","article-title":"GingisKHANTM protease cleavage allows a high-throughput antibody to Fab conversion enabling direct functional assessment during lead identification of human monoclonal and bispecific IgG1 antibodies","volume":"9","author":"Moelleken","year":"2017","journal-title":"mAbs"},{"key":"2026060911360989400_uxag029-B45","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","article-title":"Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer","volume":"32","author":"Smith","year":"2024","journal-title":"Mol Ther"},{"key":"2026060911360989400_uxag029-B46","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ajt.16828","article-title":"Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation","volume":"22","author":"Huang","year":"2022","journal-title":"Am J Transplant"},{"key":"2026060911360989400_uxag029-B47","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.4049\/jimmunol.1501929","article-title":"The bacterial enzyme IdeS cleaves the IgG-type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation","volume":"195","author":"J\u00e4rnum","year":"2015","journal-title":"J Immunol"},{"key":"2026060911360989400_uxag029-B48","doi-asserted-by":"crossref","first-page":"e0132011","DOI":"10.1371\/journal.pone.0132011","article-title":"Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS\u2014A novel therapeutic opportunity","volume":"10","author":"Winstedt","year":"2015","journal-title":"PLoS One"},{"key":"2026060911360989400_uxag029-B49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/ilar.49.2.220","article-title":"Macaque models of human infectious disease","volume":"49","author":"Gardner","year":"2008","journal-title":"ILAR J"},{"key":"2026060911360989400_uxag029-B50","doi-asserted-by":"crossref","first-page":"e1010162","DOI":"10.1371\/journal.ppat.1010162","article-title":"The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease","volume":"17","author":"Melton","year":"2021","journal-title":"PLoS Pathog"},{"key":"2026060911360989400_uxag029-B51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1568005054201508","article-title":"Non-human primate models for AIDS vaccine research","volume":"5","author":"Hu","year":"2005","journal-title":"Curr Drug Targets Infect Disord"},{"key":"2026060911360989400_uxag029-B52","first-page":"129","article-title":"Birth of rhesus macaque (Macaca mulatta) infants after in vitro fertilization and gestation in female rhesus or pigtailed (Macaca nemestrina) macaques","volume":"55","author":"Kubisch","year":"2005","journal-title":"Comp Med"},{"key":"2026060911360989400_uxag029-B53","doi-asserted-by":"crossref","first-page":"a015503","DOI":"10.1101\/cshperspect.a015503","article-title":"Primate models in organ transplantation","volume":"3","author":"Anderson","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026060911360989400_uxag029-B54","doi-asserted-by":"crossref","first-page":"e1010507","DOI":"10.1371\/journal.ppat.1010507","article-title":"A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infection","volume":"18","author":"Lawrence","year":"2022","journal-title":"PLoS Pathog"},{"key":"2026060911360989400_uxag029-B55","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX\u202f: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"key":"2026060911360989400_uxag029-B56","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.4049\/jimmunol.1003336","article-title":"Species-specific determinants in the IgG CH3 domain enable fab-arm exchange by affecting the noncovalent CH3\u2013CH3 interaction strength","volume":"187","author":"Labrijn","year":"2011","journal-title":"J Immunol"},{"key":"2026060911360989400_uxag029-B57","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1002\/cpmb.119","article-title":"Production of F(ab\u2019)2 from monoclonal and polyclonal antibodies","volume":"131","author":"Rosenstein","year":"2020","journal-title":"Curr Protoc Mol Biol"},{"key":"2026060911360989400_uxag029-B58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pep.2013.08.021","article-title":"Development of the Twin-Strep-tag\u00ae and its application for purification of recombinant proteins from cell culture supernatants","volume":"92","author":"Schmidt","year":"2013","journal-title":"Protein Expr Purif"},{"key":"2026060911360989400_uxag029-B59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","article-title":"Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles","volume":"443","author":"Brown","year":"2017","journal-title":"J Immunol Methods"},{"key":"2026060911360989400_uxag029-B60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jim.2018.01.013","article-title":"Optimization and qualification of an Fc array assay for assessments of antibodies against HIV-1\/SIV","volume":"455","author":"Brown","year":"2018","journal-title":"J Immunol Methods"},{"key":"2026060911360989400_uxag029-B61","doi-asserted-by":"crossref","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J Immunol Methods"},{"key":"2026060911360989400_uxag029-B62","doi-asserted-by":"crossref","first-page":"660900","DOI":"10.3389\/fimmu.2021.660900","article-title":"Measuring the impact of targeting FcRn-mediated IgG recycling on donor-specific alloantibodies in a sensitized NHP model","volume":"12","author":"Manook","year":"2021","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B63","doi-asserted-by":"crossref","first-page":"749891","DOI":"10.3389\/fimmu.2021.749891","article-title":"Anti-drug antibodies in pigtailed macaques receiving HIV broadly neutralising antibody PGT121","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B64","doi-asserted-by":"crossref","first-page":"105067","DOI":"10.1016\/j.isci.2022.105067","article-title":"Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses","volume":"25","author":"Lovelace","year":"2022","journal-title":"iScience"},{"key":"2026060911360989400_uxag029-B65","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4161\/mabs.25234","article-title":"Immunogenicity of mAbs in non-human primates during nonclinical safety assessment","volume":"5","author":"Van Meer","year":"2013","journal-title":"mAbs"},{"key":"2026060911360989400_uxag029-B66","doi-asserted-by":"crossref","first-page":"e0120451","DOI":"10.1371\/journal.pone.0120451","article-title":"Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques","volume":"10","author":"Rosenberg","year":"2015","journal-title":"PLoS One"},{"key":"2026060911360989400_uxag029-B67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/bdd.2222","article-title":"Validation of a de-immunization strategy for monoclonal antibodies using cynomolgus macaque as a surrogate for human","volume":"41","author":"Kovalova","year":"2020","journal-title":"Biopharm Drug Dispos"},{"key":"2026060911360989400_uxag029-B68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fimmu.2016.00589","article-title":"Biophysical and functional characterization of rhesus macaque IgG subclasses","volume":"7","author":"Boesch","year":"2016","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B69","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.4049\/jimmunol.1003336","article-title":"Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength","volume":"187","author":"Labrijn","year":"2011","journal-title":"J Immunol"},{"key":"2026060911360989400_uxag029-B70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"2026060911360989400_uxag029-B71","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V126.23.3472.3472","article-title":"M281: a therapeutic anti-FcRn blocking antibody for rapid clearance of IgG and IgG autoantibodies in immune cytopenias and other auto\/allo-immune disease","volume":"126","author":"Ling","year":"2015","journal-title":"Blood"},{"key":"2026060911360989400_uxag029-B72","doi-asserted-by":"crossref","first-page":"657424","DOI":"10.3389\/fimmu.2021.657424","article-title":"Non-neutralizing antibodies may contribute to suppression of SIVmac239 viremia in Indian Rhesus macaques","volume":"12","author":"Pedre\u00f1o-Lopez","year":"2021","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B73","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1038\/s41467-022-35340-z","article-title":"Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS","volume":"13","author":"Sudol","year":"2022","journal-title":"Nat Commun"},{"key":"2026060911360989400_uxag029-B74","doi-asserted-by":"crossref","first-page":"1608426","DOI":"10.3389\/fimmu.2025.1608426","article-title":"The FcRn from gene to protein and function: comparison between species","volume":"16","author":"Ortiz-Alegr\u00eda","year":"2025","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B75","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2133\/dmpk.DMPK-14-NT-033","article-title":"Polymorphisms of neonatal Fc receptor in cynomolgus and Rhesus macaques","volume":"29","author":"Uno","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"2026060911360989400_uxag029-B76","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ajt.15366","article-title":"The neonatal Fc receptor: key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am J Transplant"},{"key":"2026060911360989400_uxag029-B77","doi-asserted-by":"crossref","first-page":"2461191","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"mAbs"},{"key":"2026060911360989400_uxag029-B78","doi-asserted-by":"crossref","first-page":"892534","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B79","doi-asserted-by":"crossref","first-page":"e176166","DOI":"10.1172\/jci.insight.176166","article-title":"Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin","volume":"9","author":"Ma","year":"2024","journal-title":"JCI Insight"},{"key":"2026060911360989400_uxag029-B80","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026060911360989400_uxag029-B81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728214.2025.2458061","article-title":"Fcrn inhibitors in the context of myasthenia gravis","volume":"30","author":"Menon","year":"2025","journal-title":"Expert Opin Emerg Drugs"},{"key":"2026060911360989400_uxag029-B82","doi-asserted-by":"crossref","first-page":"e202451264","DOI":"10.1002\/eji.202451264","article-title":"Half-life extension of the IgG-degrading enzyme (IdeS) using FC-fusion technology","volume":"55","author":"Daventure","year":"2025","journal-title":"Eur J Immunol"},{"key":"2026060911360989400_uxag029-B83","doi-asserted-by":"crossref","first-page":"e200455","DOI":"10.1212\/NXI.0000000000200455","article-title":"Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in Myasthenia gravis: a new mechanism of action beyond IgG reduction","volume":"12","author":"Tarasco","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026060911360989400_uxag029-B84","doi-asserted-by":"crossref","first-page":"863095","DOI":"10.3389\/fimmu.2022.863095","article-title":"Fcrn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in Pemphigus vulgaris and Pemphigus foliaceus","volume":"13","author":"Maho-Vaillant","year":"2022","journal-title":"Front Immunol"},{"key":"2026060911360989400_uxag029-B85","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"2026060911360989400_uxag029-B86","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"2026060911360989400_uxag029-B87","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2018-213523","article-title":"Humanised effector-null Fc\u03b3RIIA antibody inhibits immune complex-mediated proinflammatory responses","volume":"78","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026060911360989400_uxag029-B88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/cei\/uxac112","article-title":"A novel monoclonal antibody with improved Fc\u03b3R blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose","volume":"211","author":"Nakajima-Kato","year":"2023","journal-title":"Clin Exp Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxag029\/68349208\/uxag029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag029\/68349208\/uxag029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag029\/68349208\/uxag029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:36:29Z","timestamp":1781019389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxag029\/8688569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxag029","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"uxag029"}}